Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 5/20 | 0.53 |
| ▸ | PARP1 | P09874 | 9/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700252 | 0.89 | AURKB (0.56) | AURKBPARP1PKMMAPTSMN1; SMN2 | |
| SCHEMBL4700082 | 0.88 | PARP1 (0.57) | AURKBPARP1PKMMAPTSMN1; SMN2 | |
| SCHEMBL4699791 | 0.87 | SLC2A1 (0.47) | AURKBPARP1 | |
| SCHEMBL4700064 | 0.86 | PARP1 (0.58) | AURKBPARP1TNKSTNKS2 | |
| SCHEMBL4700271 | 0.85 | PARP1 (0.49) | PARP1MAPTSMN1; SMN2KDRKMT2A | |
| SCHEMBL4702668 | 0.85 | MEN1 (0.53) | PARP1MAPTROCK2KMT2A | |
| SCHEMBL4700301 | 0.85 | PARP1 (0.56) | AURKBPARP1PKMMAPTSMN1; SMN2 | |
| SCHEMBL4701190 | 0.85 | PARP1 (0.49) | AURKBPARP1SMN1; SMN2KMT2ATNKS | |
| SCHEMBL4700321 | 0.83 | LMNA (0.55) | AURKBPARP1PKMMAPTSMN1; SMN2 | |
| SCHEMBL4698453 | 0.83 | AURKB (0.54) | AURKBPARP1PKMMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | claimed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | claimed |
| US-7432263-B2 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA, S.R.L. (IT) | 2008-10-07 | — | — | US | disclosed |
| EP-1427708-B1 | AMINO-PHTHALAZINONE DERIVATIVES AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER ITALIA SRL (IT) | 2008-09-10 | — | — | EP | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| EP-1427708-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-16 | — | — | EP | disclosed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | disclosed |
| WO-2003014090-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K15, MAP3K5 | AURKB 180/4885PARP1 1385/4885PKM 257/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | AURKB 115/4885PARP1 1467/4885PKM 175/4885 |
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | AURKB 4820/4885PARP1 1908/4885PKM 1331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.